Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
Vergote, Ignace; Van Nieuwenhuysen, Els; O'Cearbhaill, Roisin Eet al.
2023 • In Journal of Clinical Oncology, p. 2300720
[en] [en] PURPOSE: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).
METHODS: This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR).
RESULTS: A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E).
CONCLUSION: TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.
Disciplines :
Oncology
Author, co-author :
Vergote, Ignace ; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, Leuven, Belgium
Van Nieuwenhuysen, Els; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, Leuven, Belgium
O'Cearbhaill, Roisin E ; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
Westermann, Anneke ; Dutch Gynaecological Oncology Group, Amsterdam University Medical Centers, Amsterdam, the Netherlands
Lorusso, Domenica ; Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Catholic University of Sacred Heart, Rome, Italy
Ghamande, Sharad; Department of Obstetrics and Gynecology, Augusta University, Augusta, GA
Collins, Dearbhaile C ; Department of Medical Oncology, Cancer Trials Ireland, Cork University Hospital, Cork, Ireland
Banerjee, Susana ; Royal Marsden National Health Service Foundation Trust, Institute of Cancer Research, London, United Kingdom
Mathews, Cara A ; Program in Women's Oncology, Women & Infants Hospital, Legorreta Cancer Center at Alpert Medical School of Brown University, Providence, RI
Gennigens, Christine ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Cibula, David ; Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
Tewari, Krishnansu S ; University of California, Irvine, CA
Madsen, Kristine; Centre for Cancer and Organ Diseases, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
Köse, Fatih; Baskent University, Ankara, Turkey
Jackson, Amanda L; Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati, OH
Boere, Ingrid A ; Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
Publication date :
31 August 2023
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology (ASCO), United States
Gargano JW, McClung N, Lewis RM, et al.: HPV type-specific trends in cervical precancers in the United States, 2008 to 2016. Int J Cancer 152: 137-150, 2023
Pfaendler KS, Tewari KS,: Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214: 22-30, 2016
Siegel RL, Miller KD, Wagle NS, et al.: Cancer statistics, 2023. CA Cancer J Clin 73: 17-48, 2023
Tewari KS, Sill MW, Long HJ 3rd, et al.: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370: 734-743, 2014
Chuang LT, Temin S, Camacho R, et al.: Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. JCO Glob Oncol 2: 311-340, 2016
Colombo N, Dubot C, Lorusso D, et al.: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 385: 1856-1867, 2021
Chuang LT, Temin S, Berek JS,: Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update. JCO Glob Oncol 8: e2200027, 2022
Alholm Z, Monk BJ, Ting J, et al.: Patient characteristics, treatment patterns and clinical outcomes among patients with previously treated recurrent or metastaticcervical cancer: a community oncology-based real-world analysis Annual Meeting of the Society of Gynecologic Oncology Women's Cancer, virtual, March 19-25, 2021 (poster)
Musa FB, Brouwer E, Ting J, et al.: Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer. Gynecol Oncol 164: 645-650, 2022
Alholm Z, Monk BJ, Ting J, et al.: Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis. Gynecol Oncol 161: 422-428, 2021
de Bono JS, Harris JR, Burm SM, et al.: Systematic study of tissue factor expression in solid tumors. Cancer Rep 6: e1699, 2022
Alley SC, Harris JR, Cao A, et al.: Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro. Cancer Res 79: 221, 2019
Breij EC, de Goeij BE, Verploegen S, et al.: An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 74: 1214-1226, 2014
Coleman RL, Lorusso D, Gennigens C, et al.: Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22: 609-619, 2021
Vergote I, Coleman RL, Pignata S, et al.: Joint ENGOT and GOG Foundation requirements for trials with industry partners. Int J Gynecol Cancer 29: 1094-1097, 2019
Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009
Alholm Z, He D, Ting J, et al.: Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis. Gynecol Oncol 166: 567-575, 2022
Sonawane K, Castellano T, Washington C, et al.: Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis. Gynecol Oncol Rep 44: 101121, 2022
Hong DS, Concin N, Vergote I, et al.: Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 26: 1220-1228, 2020
Yonemori K, Kuboki Y, Hasegawa K, et al.: Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. Cancer Sci 113: 2788-2797, 2022
Chung HC, Ros W, Delord JP, et al.: Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 37: 1470-1478, 2019
Nishio S, Yonemori K, Usami T, et al.: Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826. Cancer Sci 113: 3877-3887, 2022
Tewari KS, Sill MW, Penson RT, et al.: Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390: 1654-1663, 2017
Sugiyama T, Mizuno M, Aoki Y, et al.: A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer. Jpn J Clin Oncol 47: 39-46, 2017
